Last updated: May 22, 2026
Anafranil is the U.S.-market brand of clomipramine, a tricyclic antidepressant (TCA) long approved for obsessive-compulsive disorder (OCD). There is no current pattern of late-stage (Phase 3) brand-development trials that would materially reset exclusivity. The competitive outlook is dominated by generics and price competition in mature markets, with clinical-development attention typically shifting to next-generation formulations, new dosing regimens, and label expansions rather than restarting primary regulatory exclusivity.
Anafranil clinical trials update: what studies are active and what endpoints matter
Quick answer: Recent public activity in clomipramine is dominated by academic or small-company studies rather than large Phase 3 programs expected to support new regulatory exclusivity in the U.S. or EU.
Are there any Phase 3 trials for Anafranil right now?
Quick answer: Public registries do not show a widely reported, recruiting or active Phase 3 registration trial for clomipramine specifically labeled as “Anafranil” intended to support a new FDA indication. The clinical trial footprint is typically smaller and used to refine use in OCD subpopulations or compare clomipramine against other strategies.
What trial endpoints are most relevant to clomipramine in OCD
Common endpoints in OCD trials (and the ones that carry the most translational weight for label change) include:
- Yale-Brown Obsessive Compulsive Scale (Y-BOCS) change from baseline
- Responder rates (often 25% or 35% Y-BOCS reduction)
- Time-to-response or durability endpoints in relapse or maintenance phases
- Safety endpoints that are material for TCAs, including QT/QRS conduction measures, orthostatic hypotension, and anticholinergic burden
What dosing and formulation questions drive today’s clinical studies
Clomipramine’s development pattern in mature therapy areas tends to focus on:
- Switching from immediate-release to modified-release formulations to smooth peak exposure
- Cross-over designs to evaluate tolerability differences
- Lower discontinuation rates from adverse events
- Pharmacokinetic bridging and food-effect studies for reformulations
Anafranil market analysis: how big is the clomipramine franchise and what drives revenue
Quick answer: Anafranil is a mature, high-generics-exposure asset. Revenue is driven by continued branded penetration where generics are less preferred, where payers restrict alternatives, and where therapeutic switching is delayed by tolerability or clinical inertia.
U.S. market structure: brand vs generic dynamics
Anafranil faces structural pressure from:
- Established generic clomipramine tablets/capsules and pricing compression
- Formulary tiering that favors low-cost generics
- Ongoing prescriber behavior that may reduce conversions after stabilization
Key market drivers
- OCD patient churn: OCD is chronic, so stable patient cohorts exist, but new starts can be price-sensitive and generic-driven
- Safety/tolerability: TCAs have a narrower tolerability window than many newer agents, which can affect switching behavior
- Payer management: step edits and prior authorizations can influence brand adoption even in the presence of generics
Competitive set
The relevant therapeutic competitive set in OCD includes:
- SSRIs (first-line pharmacotherapy class)
- Serotonin-norepinephrine reuptake inhibitors (selected patients)
- Augmentation strategies (antipsychotics as adjuncts in refractory cases)
- Behavioral therapy (ERP) as a key comparator in outcomes models
When does Anafranil lose exclusivity in the US and EU?
Quick answer: Anafranil’s original regulatory exclusivities based on its initial approval have long elapsed. Today’s exclusivity question is not primary exclusivity. It is about whether any newer patents cover specific formulations, methods of treatment, or manufacturing steps and whether any remain enforceable.
Patent and exclusivity posture
For mature clomipramine, the enforceable landscape typically consists of:
- Composition-of-matter or formulation patents tied to specific dosage forms (if still active)
- Method-of-use patents (for specific OCD subtypes, dosing regimens, or augmentation strategies)
- Manufacturing process patents (rare to materially block generic supply unless tightly scoped)
What formulations are protected for Anafranil and how does that affect generic entry risk?
Quick answer: Generic entry risk for clomipramine is usually low unless a specific formulation or process is protected. In mature markets, the generic threat is often structural rather than patent-driven.
Generic entry barriers to model
- Patent “product-by-process” or specific manufacturing controls can delay certain filings even with active ingredient equivalence
- Formulation patents can block entry for that specific dosage form even if other strengths are already generic
- If no active formulation restrictions exist, generics are primarily constrained by supply chain and labeling logistics rather than litigation
How strong is the patent estate for clomipramine (Anafranil)
Quick answer: For established small molecules like clomipramine, the practical enforcement horizon usually narrows to the edges: narrow method-use or specific formulation claims. Broad compound exclusivity is typically not the binding constraint anymore.
Patent estate elements to diligence
- Active claims covering specific dosage forms and strengths
- Method-of-use claims that tie to OCD patient subsets or defined treatment regimens
- Geographic scope: U.S. enforceability versus EU member state differences in patent enforcement
What Paragraph IV challenges exist for Anafranil?
Quick answer: There is no widely documented, ongoing wave of high-profile Paragraph IV challenges for Anafranil typical of current-cycle blockbuster transitions. The market is mature and generics already established.
What to model even if no active Paragraph IV dominates
- Niche challenges around specific strengths/formulations where exclusivity barriers remain
- Litigation outcomes that affect distribution networks and pharmacy reimbursement patterns
Orange Book status of Anafranil: what is listed and why it matters
Quick answer: The Orange Book listing supports generics and is used to evaluate whether any remaining patents are listed for the relevant NDA and dosage forms. For clomipramine, most competitive pressure typically comes from the presence of multiple generic approvals rather than from active Orange Book blocks.
How Orange Book data maps to competitive forecasts
- If listed patents are expired: generic entry is likely via non-proprietary pricing
- If listed patents remain: watch the NDA-to-ANDAs mapping and any exclusivity code indicators for timing
What generic entry scenarios exist for Anafranil and how do they change price
Quick answer: The realistic scenario is not “first generic entry.” It is deeper price compression, channel reshuffling, and reduced brand share as payer coverage shifts.
Entry scenarios that change forecasts
- New generic entrants for previously less competitive strengths
- Supply expansions that increase pricing elasticity
- Labeling or formulation changes that reintroduce switching decisions
What biosimilar risk exists for Anafranil?
Quick answer: None. Anafranil is a small-molecule TCA, not a biologic.
What manufacturing/IP barriers affect clomipramine supply and continuity
Quick answer: Barriers are typically regulatory and supply chain driven rather than IP driven at this stage.
Continuity risks to monitor
- API sourcing concentration and regional manufacturing capacity
- Lot-release delays tied to controlled substances classification, where applicable
- Quality events that cause temporary backorders, which can temporarily improve branded positioning even when fundamentals favor generics
Commercial projection for Anafranil and clomipramine: base case, downside, upside
Quick answer: With generics entrenched, the base-case forecast is gradual erosion or flat branded revenue with periodic spikes from supply and payer dynamics. Growth is generally limited unless driven by new label indications, breakthrough formulations, or payer repositions.
Base case (most likely):
- Branded share trends lower or stays flat
- Net pricing continues to compress
- Volume stabilizes due to chronic treatment inertia
Downside case:
- Further payer restrictions against brand
- Additional generic competition increases channel share transfer
- Supply normalization removes any temporary branded uplift
Upside case:
- A new dosing/formulation improves tolerability and sustains brand preference
- Targeted patient cohorts expand based on clinician adoption or new evidence
- A shortage causes short-term brand share and pricing lift
Model drivers that should control the forecast
- Generic weighted average price (WAC) movements
- Formulary tiering changes and utilization management tightening
- Wholesale acquisition price adjustments and rebate dynamics
- Any Orange Book patent expiration events that clear the way for additional ANDA entrants
Key takeaways
- Anafranil (clomipramine) is a mature small-molecule franchise with competitive pressure dominated by generics rather than active regulatory exclusivity resets.
- Clinical-development updates are unlikely to include large, label-changing Phase 3 programs that would materially extend exclusivity.
- Market projections should model generic-driven price compression, payer-driven utilization management, and episodic supply-chain effects rather than new innovation-based growth.
- The actionable diligence focus is Orange Book status for specific dosage forms and any narrow, still-enforceable patents tied to formulation or method-of-use claims.
FAQs
- Does Anafranil have any remaining FDA exclusivity protections for OCD?
- Are there active clinical trials comparing clomipramine to SSRIs or ERP in OCD?
- Which Anafranil dosage forms have the highest generic substitution risk?
- How do QT prolongation and TCA cardiac risks influence prescribing and payer rules for clomipramine?
- What supply shortages or manufacturing quality events most often impact clomipramine availability and pricing?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book)
- ClinicalTrials.gov. Search results for clomipramine and OCD. (ClinicalTrials.gov)
- U.S. Food and Drug Administration. Drug Approval Package: Anafranil (clomipramine). (FDA)
